One-Year Outcomes of M-TEER With the PASCAL System in Atrial and Ventricular FMR: Insights From the MiCLASP Postmarket Clinical Follow-Up Study

doi:10.1161/circinterventions.126.016563

Valvular & structural heart diseaseResearch article

One-Year Outcomes of M-TEER With the PASCAL System in Atrial and Ventricular FMR: Insights From the MiCLASP Postmarket Clinical Follow-Up Study

Circ Cardiovasc IntervPublished 25 Aug 2026

multicenter European postmarket clinical follow-up study

Read the original article ↗

Authors' conclusion

One-year MiCLASP results support the safety of mitral transcatheter edge-to-edge repair with the PASCAL system in both AFMR and VFMR, with comparable echocardiographic, functional, and quality-of-life changes, despite baseline differences in clinical presentation.

Study context

Population: Patients with functional mitral regurgitation (atrial functional mitral regurgitation (AFMR) or ventricular functional mitral regurgitation (VFMR)) undergoing mitral transcatheter edge-to-edge repair with the PASCAL systemfrom the first 600 enrolled in the MiCLASP study · AFMR 52 · VFMR 243
Participants: 295 patients

Comparison: AFMR vs VFMR
AFMRn = 52
VFMRn = 243

Main finding

As reported in the abstract

Procedural success

AFMR96.2%

VFMR97.1%

Further findings

Procedure duration

AFMR73.5 minutes

VFMR85.5 minutes

Freedom from all-cause mortality or heart failure hospitalizations (Kaplan-Meier estimate) · One-year

AFMR79.3%

VFMR70.9%

Echocardiographic, functional and quality-of-life outcomes · One-year

mitral regurgitation ≤1+

AFMR93.1%

VFMR81.3%

mean transmitral gradient AFMR 3.5 mm Hg · VFMR 3.1 mm Hg

left ventricular end-diastolic volume AFMR −12.9% · VFMR −16.4%

left atrial volume AFMR −9.6% · VFMR −10.9%

New York Heart Association class I/II

AFMR76.5%

VFMR64.6%

Kansas City Cardiomyopathy Questionnaire Overall Summary score AFMR +18.0 points · VFMR +11.6 points

Baseline characteristics

age AFMR 79.7±6.67 years · VFMR 74.6±10.30 years

female

AFMR75.0%

VFMR33.3%

hypertension

AFMR98.1%

VFMR82.3%

atrial fibrillation

AFMR82.7%

VFMR60.1%

NT-proBNP AFMR 1562.0 [790.0-2286.0] · VFMR 3350.0 [1720.0-6564.0]

mitral regurgitation ≥3+

AFMR46.2%

VFMR71.9%

Procedure duration: P =0.044
Freedom from all-cause mortality or heart failure hospitalizations (Kaplan-Meier estimate): P =0.267
Echocardiographic, functional and quality-of-life outcomes: all P <0.05 from baseline
Baseline characteristics: age, sex, hypertension, atrial fibrillation: all P <0.05
Baseline characteristics: NT-proBNP P <0.001
Baseline characteristics: mitral regurgitation ≥3+ P <0.001

Original publication

One-Year Outcomes of M-TEER With the PASCAL System in Atrial and Ventricular FMR: Insights From the MiCLASP Postmarket Clinical Follow-Up Study. Circ Cardiovasc Interv. Published 25 August 2026. doi:10.1161/circinterventions.126.016563

Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it